arrow
N

Nicolas Penel

centre oscar lambret
H指数:76
被引数:2.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Molecular profiling and access to treatment for rare cancers in Europe

欧洲罕见癌症的分子分型与治疗可及性

2026-07-230
OA
Characteristics and outcome of intra-abdominal desmoid-type fibromatosis

腹内型硬纤维瘤的特征和预后

2026-05-190
PRE
Linking the NETSARC plus National Sarcoma Database With the SNDS to Evaluate Adjuvant and/or Neoadjuvant Therapy: Report on the Linkage Process and Result (Health Data Hub's DEEPSARC Pilot Project)

将NETSARC plus国家肉瘤数据库与SNDS连接以评估辅助和/或新辅助治疗:连接过程与结果报告(健康数据中心DEEPSARC试点项目)

2026-01-010
OAAI
Outcome of patients with curative-intent treatment for primary pulmonary sarcoma: Results from an international multicenter retrospective study

原发性肺肉瘤根治性治疗患者的结局:一项国际多中心回顾性研究的结果

2025-12-011
OAAI
Corrigendum to “Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)”

“索拉非尼在局部晚期和转移性脊索瘤患者中的应用: 法国肉瘤组 (GSF/GETO) 的II期试验”

2025-10-150
PRE
Outcome of 1773 superficial non-dermatofibrosarcoma sarcomas A French Sarcoma Group study (FSG) from the NETSARC database

1773例非皮肤纤维肉瘤浅表肉瘤的结局:一项来自NETSARC数据库的法国肉瘤组(FSG)研究

2025-09-120
PRE
Clinical and biological factors associated with response to immune checkpoint inhibitors in advanced sarcomas: IMPRESARC, a French retrospective multicenter cohort study

与免疫检查点抑制剂应答相关的临床和生物学因素:晚期肉瘤的IMPRESARC研究——一项法国回顾性多中心队列研究

Cancer
IF5.1
2025-09-050
OAAI
Clinical presentation, management and outcome of 11,132 patients with liposarcoma patients: a population-based study from the NETSARC+ registry

临床表现、治疗管理及结局:11,132例脂肪肉瘤患者的流行病学研究(基于NETSARC+登记系统)

2025-07-310
PREAI
COREGO: drug–drug interaction analysis on the efficacy and safety of regorafenib in patients with a sarcoma: pooled analysis of the data from the REGOSARC and REGOBONE trials

COREGO:regorafenib在软组织肉瘤患者中的药物相互作用对疗效和安全性的影响:REGOSARC和REGOBONE试验数据的合并分析

2025-06-010
PRE
Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial

接受伊马替尼治疗的晚期胃肠道间质瘤的二十年生存率:BFR14试验的探索性长期随访

2025-05-280
OAAI
Targeting ATF6α Attenuates UVB-Induced Senescence and Improves Skin Homeostasis by Regulating IL8 Expression
2025-04-160
PRE
Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial☆

瑞戈非尼作为一线多柔比星类化疗后的维持疗法在进展期非脂肪源性软组织肉瘤患者中的应用:一项双盲随机试验☆

2025-04-080
PRE
Clinical description and development of a prognostic score for neurofibromatosis type 1 (NF1)-associated GISTs: a retrospective study from the NETSARC

神经纤维瘤病1型(NF1)相关胃肠道间质瘤(GISTs)的临床描述及预后评分的开发:一项来自NETSARC的回顾性研究

2025-03-010
OAAI